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ABSTRACT: A series of 5-aryl-2-amino-imidazothiadiazole (ITD)
derivatives were identiﬁed by a phenotype-based high-throughput
screening using a blood stage Plasmodium falciparum (Pf) growth
inhibition assay. A lead optimization program focused on improving
antiplasmodium potency, selectivity against human kinases, and
absorption, distribution, metabolism, excretion, and toxicity properties and extended pharmacological proﬁles culminated in the
identiﬁcation of INE963 (1), which demonstrates potent cellular
activity against Pf 3D7 (EC50 = 0.006 μM) and achieves
“artemisinin-like” kill kinetics in vitro with a parasite clearance
time of <24 h. A single dose of 30 mg/kg is fully curative in the Pfhumanized severe combined immunodeﬁcient mouse model. INE963 (1) also exhibits a high barrier to resistance in drug selection
studies and a long half-life (T1/2) across species. These properties suggest the signiﬁcant potential for INE963 (1) to provide a
curative therapy for uncomplicated malaria with short dosing regimens. For these reasons, INE963 (1) was progressed through GLP
toxicology studies and is now undergoing Ph1 clinical trials.

■

INTRODUCTION

Artemisinin derivatives are highly potent and fast-acting
antimalarials that produce rapid clinical responses to treatment. However, there has been an increasing number of
reports of artemisinin-resistant malaria in the Greater Mekong
subregion,2 and in addition, resistance against partner drugs
such as meﬂoquine and piperaquine is already widespread.3,4
Furthermore, recent reports of dihydroartemisinin-piperaquine
treatment failures have been documented.5 The emergence of

Malaria is the world’s most prevalent infectious and lifethreatening disease, caused by the protozoan parasite
Plasmodium that is transmitted to human hosts by female
Anopheles mosquitoes. In 2019, there were an estimated 229
million cases and 409,000 deaths, mostly aﬀecting children
aged under 5 years. Nearly half of the world’s population is at
risk of malaria infection. Most malaria cases and deaths occur
in sub-Saharan Africa, while South-East Asia, Eastern
Mediterranean, Western Paciﬁc, and the Americas are also at
risk. Currently artemisinin-based combination therapy is
recommended as a ﬁrst-line treatment for uncomplicated
malaria caused by Plasmodium falciparum (Pf) and has proved
eﬀective in reducing the disease burden.1
© 2022 The Authors. Published by
American Chemical Society
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margin to progress this compound further. Thus, to assess the
broader human kinase inhibition proﬁle of 3, the binding
aﬃnities to 468 human kinases were tested at a 10 μM
concentration. Compound 3 inhibited 53 out of 468 human
kinases at <10% of control (Figure 6), which we suspected was
directly impacting the rat and dog toxicology ﬁndings and was
likely a major factor resulting in the narrow safety margins
observed.
Additionally, we observed that the in vitro potency of 3
decreased over time after multiple rounds of testing (EC50 =
1.16 μM), indicating that 3 was likely degrading in DMSO
stock solution. Chemical stability analysis revealed that the
crystalline malate salt of 3 degraded over 24 h to 2.6% and
77.4% of the parent in pH 6.8 and fasted state simulated
intestinal ﬂuid (FaSSIF) solutions, respectively. Although 3
was chemically stable in the solid state, the solution instability
was deemed a development risk. An additional analysis using
2D NMR elucidated the structure of the degraded product C/
D, which suggested tautomerization of the 2-amino-ITD
moiety to the 2-imino-thiazolidine A. This tautomer A can
be a trigger of nucleophilic cyclization by the terminal amine
and result in spiro-cycle B, thereby leading to the degradation
product C/D as illustrated in Figure 2.

artemisinin resistance is a real threat to malaria treatment and
elimination eﬀorts worldwide.6 As a consequence, there is still
an urgent need to identify new antimalarial compounds that
can be added to or substitute the current artemisinin-based
therapies. The artemisinin family has a short half-life and needs
to be combined with a longer-acting partner drug for complete
clearance of parasites.7 Therefore, our goal at the Novartis
Institute for Tropical Diseases (NITD) is to identify a fastacting antimalarial compound from a novel chemotype with
activity against known resistance mutations and which will also
have the potential for single-dose cures.8 Novel antimalarial
chemotypes are expected to have a diﬀerent mode of action to
current drugs, and thus no cross resistance. In recent years,
phenotype-based approaches have proven successful for the
identiﬁcation of new antimalarial chemotypes with novel
modes of action, and as a result, several lead candidates such as
KAE609,9 KAF156,10 DSM265, 11 MMV048,12 SJ733,13
M5717,14 and ZY1948915 have been advanced to clinical trials
to show activity in patients.
In our continued research eﬀorts at NITD to identify new
antimalarial leads, our phenotypic screening campaigns and
subsequent follow-up structure−activity relationship (SAR)
studies around various hit series resulted in the identiﬁcation of
the 5-aryl-2-amino-imidazothiadiazole (ITD) lead compound,
2, which displayed modest potency (EC50 of 0.27 μM) against
the cultured parasite Pf 3D7 (Figure 1). During optimization

Figure 1. Early and late lead 5-aryl-2-amino-ITD antiplasmodium
compounds discovered by Novartis and 5-aryl-2-amino-ITD hit
disclosed by MMV.

Figure 2. Putative mechanism of tautomerization and degradation of
3.

of the scaﬀold, the late-lead compound 3 was rapidly identiﬁed
with improved potency (EC50 = 0.025 μM) and excellent in
vivo pharmacokinetics. Compound 3 demonstrated a single
dose ED90 of 5.3 mg/kg against Pf infected mice and a similar
speed-of-action to artemisinin. In addition, a single dose of 50
mg/kg was fully curative with no observed recrudescence after
60 days (Table 8). During our early studies of the 5-aryl-2amino-ITD chemical series, Medicines for Malaria Venture
(MMV) independently conducted a high-throughput screen of
a chemical library consisting of more than 250,000 compounds
against blood-stage Pf.16 Structures of 15 validated hits were
disclosed, including the 5-aryl-2-amino-ITD analog 4. Compound 4 was resynthesized in our laboratories for biological
characterization and conﬁrmed potent antiplasmodium activity
with an EC50 of 0.021 μM.
Despite the promising in vitro and in vivo antimalarial
proﬁles of this ITD series, we were concerned about the oﬀtarget selectivity given that a related chemical series of 5-aryl-2amino-ITDs are described in the patent literature as potent
inhibitors of human kinases (e.g., FLT3, PIK3CA, and
PIM1).17,18 In addition, early animal toxicology studies of 3
in rats and dogs indicated that there was not an adequate safety

Therefore, we undertook lead optimization of the 5-aryl-2amino-ITD series to address the issues of chemical stability
and human kinase promiscuity, while maintaining or improving
the desirable pharmacological and safety properties. Herein, we
describe a phenotype-based SAR study around the 5-aryl-2amino-ITD scaﬀold with a focus on selectivity against human
kinases and optimization of physiochemical and absorption,
distribution, metabolism, and excretion (ADME) properties
suitable for a single-dose cure therapy in uncomplicated
malaria.

■

RESULTS AND DISCUSSION
The proposed mechanism of tautomerization and chemical
degradation suggested that removing the hydrogen of the 2N(H)R linker would improve the chemical stability of the 5aryl-2-amino-ITD scaﬀold. In addition, we had observed early
on that related compounds which replaced the 2-N(H)R with
a 2-N(Me)R linker were more chemically stable and
maintained good potency. We were then pleased to ﬁnd that
the cyclic 4-methyl-4-amino-piperidine analog, 5, provided a
3799
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further reducing the Haspin inhibition while retaining potency.
However, shifting the position of the ether oxygen of 13 to 2CH2OMe (15) decreased potency (EC50, 0.11 μM). The 2OCH2CH2OMe polar side chain (16) also led to weaker
potency. The dihydrobenzofuran (17) had similar antiplasmodium potency and Haspin inhibitory activity to 9, while the
indole (18) and N-methylindole analog (19) were less potent.
Introduction of the pyridine nitrogen to 9 yielded the 2-ﬂuoro6-OMe pyridine (20), which had similar antiplasmodium
activity but 2−3 fold lower selectivity against Haspin. The
regioisomeric 2-OMe-pyridine analog (21) further decreased
selectivity against Haspin. Heteroaromatics such as pyrimidine
and thiazole were signiﬁcantly less potent (22−26).
Several nonaromatic moieties were also examined. The tertbutylacetylene analog (27) had good antiplasmodium potency
and maintained good selectivity against Haspin, however the
cyclopropylacetylene (28) dropped the potency by 3-fold and
the propargyl alcohol (29) was not tolerated. Cyclohexene
(30) retained good antiplasmodium potency, but lost Haspin
selectivity. Conversely, 4,4-diﬂuorocyclohexane (31) and
cyclopentane (32) moieties led to a signiﬁcant loss of the
antiplasmodium activity.
Compound 9 was then selected for in vitro proﬁling where it
exhibited improved chemical stability in FaSSIF solution
(compared to 3) and retained good metabolic stability (Table
3). Compound 9 also demonstrated a lower aﬃnity against a
small panel of selected human kinases in addition to Haspin
(CDK7, FLT3, KIT, PIM-1,2,3), suggesting that the 2-OMearyl substituent reduces overall human kinase promiscuity.
During this SAR study at the 5-position of the ITDs, an Xray cocrystal structure of the 2,4-diﬂuorobenzene compound 5
with Haspin was solved with a resolution of 1.8 Å (Figure 3).
Interestingly, the ITD core is bound to the hinge region via
one H-bond between the 7-nitrogen atom and G608 (2.9 Å)
and a σ−hole interaction of sulfur with G609 (3.4 Å). The
costructure also shows a clear salt bridge interaction between
D611 (2.8 Å) of the lower hinge and the ammonium cation of
5. This binding mode of the ITD core projects the 2,4diﬂuorobenzene ring in a coplanar fashion which binds to
Haspin in a hydrophobic pocket with close contact (<3.5 Å) of
nearby residues and sheds light on our observed SAR of the 2OMe or 3-OMe aryl analogs. This hydrophobic pocket likely
causes a steric clash with 2-OMe or 3-OMe aryl ITD analogs,
mitigating aﬃnity to and inhibition of Haspin kinase while still
allowing potent antiplasmodium activity (9 and 12). This
theory for antiplasmodium vs human kinase selectivity is
further exempliﬁed by the good potency of 4-OMe analogs in
both Plasmodium and Haspin assays (10), where there appears
to be more room in the Haspin binding pocket. To further
probe this binding mode, we introduced a methyl group
directly to the 6-position of the ITD core to obtain 33, which
led to a signiﬁcant loss of both antiplasmodium and Haspin
activities. Similarly, additional minor modiﬁcations of the ITD
core resulted in signiﬁcant loss of antiplasmodium potency, for
example, the replacement of the nitrogen with carbon at the 3position (i.e., imidazothiazole) 34 (Figure 4).
Optimization of the 2-Amino-Alkyl Side Chain of
ITDs. Although 9 addressed the issues of the chemical stability
and kinase promiscuity, we saw opportunities to further
improve upon the potential cardiosafety risk (hERG Qpatch
IC50 = 2.4 μM) and absorption, distribution, metabolism,
excretion, and toxicity properties. Consequently, the next
phase of optimization focused on modiﬁcations to the 2-

2.5-fold increase in antiplasmodium activity along with
increased chemical stability. In addition, replacement of the
2-amino-linker with a 2-carbon-linker, 6 and 7, was also
tolerated albeit with slightly lower potency. It is hypothesized
that preventing tautomerization as well as the increasing
rigidity of the side chain both improve chemical stability.
Unexpectedly, replacement of the 2-amino-linker with an ether
or thioether resulted in a dramatic loss in antiplasmodium
activity. Considering the best potential to combine chemical
stability, antiplasmodium potency, and synthetic tractability, 5
was selected as a starting point for further optimization (Table
1).
Table 1. In Vitro Antiplasmodium Activity of 2-Amino and
2-Carbon Linked ITD Analogs

a
EC50 values are given as average potency values in the Pf 3D7 assay
(n ≥ 3). Standard control meﬂoquine has an EC50 value of 0.034 uM.

SARs for Pf 3D7 Activity and Selectivity against
Human Haspin Kinase. We ﬁrst investigated the antiplasmodium SAR as well as the human kinase selectivity by
systematic modiﬁcations of the 2,4-diﬂuorobenzene moiety of
5 (Table 2). Haspin kinase proved to be the most sensitive and
was used as the benchmark for selectivity comparisons. The
IC50 value of late lead compound 3 against Haspin was
determined to be 0.011 μM. In addition, the screening hit 4
published by MMV, and our starting point 5, showed a similar
Haspin inhibitory activity compared to 3. Replacement of the
2-F with 2-Me (8) and 2-OMe (9) reduced the Haspin
inhibition to IC50’s of 1.28 and 1.74 μM, respectively, while
maintaining antiplasmodium activity. Exchanging the 4-F to 4OMe (10) decreased Haspin selectivity. Transposition of the
4-F to 6-F to give the 2,6-disubstituted analog (11) resulted in
a 10-fold drop in antiplasmodium potency, presumably due to
an increase in the biaryl dihedral angle (based on the observed
orientation of compound 5 in the X-ray structure; Figure 3).
The 3-OMe, 2-F analog (12) had a similar potency and
selectivity as compared to 9, supporting the observation that
the 2-OMe or 3-OMe substituent improves selectivity against
Haspin. Replacement of the 2-OMe substituent with sterically
larger groups such as −OEt (13) and −O-iPr (14) resulted in
3800
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Table 2. SAR of the 5-Position of ITDs

EC50 and IC50 values given as averages (n ≥ 3 unless otherwise noted). Standard control meﬂoquine has an EC50 value of 0.034 uM.

a
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Table 3. Summary of Key Data for 9 for Comparison to 3

Figure 3. X-ray cocrystal structure of 5 (green) with Haspin kinase.
PDB code is 7SQM.

amino-alkyl side chain of the ITD series with an emphasis on
reducing the lipophilicity and pKa, while maintaining
antiplasmodium activity. Introduction of a hydroxyl group
adjacent to the basic amino group led to several vicinal aminoalcohol substituted piperidine analogs, most of which displayed
a decreased hERG inhibition with IC 50 ’s > 20 μM.
Enantiomers 35 and 36 displayed a slight improvement in
cell LipE (lipophilic ligand eﬃciency, LipE = pEC50 − log D7.4)
with a lower pKa compared to 9, while there is no enantiomeric
preference for antiplasmodium activity. Both 35 and 36 have
acceptable liver microsomal stability and exhibited good in vivo
oral exposure proﬁles in rats (Table 4). Further reduction of
lipophilicity by removing the 4-methyl group of the piperidine
ring led to trans-amino-alcohol enantiomers, 37 and 38, which
displayed an improvement in cell LipE while maintaining good
metabolic stability and reduced pKa, however lower oral
exposure was observed in rats with 37 presumably due to a
slight drop in permeability and volume. The corresponding cisamino-alcohol piperidine isomers, 39 and 40, were slightly less
potent on Plasmodium, despite their higher basicity. Transposition of the amino-alcohol provided another enantiomeric
pair of cis-amino-alcohol analogs, 41 and 42, which showed
similar antiplasmodium activity (EC50 = 0.029 μM) with lower
basicity (pKa 7.8), however both enantiomers increased the
hERG inhibition (IC50 < 20 μM) and 41 had low oral exposure
in rats despite its good metabolic stability. The corresponding
trans-amino-alcohol analogs, 43 and 44, further reduced the
pKa to 7.5, however the Plasmodium potency was also slightly

Figure 4. Key SAR of ITD-analogs on HASPIN kinase and Pf.

diminished (EC50’s = >0.030 μM). Replacement of the
hydroxyl group in 39 and 40 with ﬂuorine led to cis-4amino-3-ﬂuoro-piperidine isomers 45 and 46, which decreased
cellular LipE and increased the hERG inhibition. The
corresponding trans-4-amino-3-ﬂuoro-piperidine analog 47
further diminished the Plasmodium potency. Ring contraction
led to cis-4-amino-3-hydroxy-pyrrolidine and 3-amino-3hydroxymethyl pyrrolidine analogs as enantiomeric pairs (48
and 49, 50 and 51). While these pyrrolidine analogs had
3802
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Table 4. SAR of the 2-Amino-alkyl Groupa
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Table 4. continued

a

Peak-1: Fast-eluting isomer from chiral HPLC. Peak-2: Slow-eluting isomer from chiral HPLC. HLM: Human liver microsomes. RLM: Rat liver
microsomes. Cmax, AUC: mean blood concentration time proﬁle from oral administration to rats at 10 mg/kg.

increased tissue binding and volume of distribution (Vss),
thereby increasing the half-life (T1/2) and improving in vivo
eﬃcacy. However, increasing lipophilicity often adversely
aﬀects metabolic stability and oﬀ-target selectivity. Therefore,
our ambition was to ﬁnd the most suitable substitution of the
5-aryl-group to combine with the 4-(aminomethyl)piperidin-4ol side chain and provide a compound with balanced polarity
and ideal drug-like properties. To assess the optimal properties
for in vivo eﬃcacy, human and rat hepatocyte clearance as well
as oral exposure in rats were determined, including the ratio of
48 h concentration over Pf EC50 as a pharmacokinetic/
pharmacodynamic (PK/PD) surrogate for maintaining a high
parasiticidal concentration over one parasite life-cycle.
Homologation of the 2-OMe group to the 2-OEt group (64)
slightly improved the potency but led to lower cell LipE and 2fold lower oral exposure as compared to 55 (Table 5).
Interestingly, the C48 h/EC50 was slightly improved (10.8 vs
9.1) despite the lower exposure. Replacement of the paraﬂuoro with a methyl group provided 65, which displayed a
hERG IC50 of >30 μM with comparable Plasmodium potency
to 55. Moreover, 65 had a similar oral exposure with 2-fold
higher C48 h/EC50 ratio (18.6 vs 9.1) than 55. It was then
hypothesized that introduction of a nitrogen in the ring at the
meta-position (adjacent to both ortho-OMe and para-Me)
would mitigate lipophilicity and metabolism, while still being
shielded from intermolecular interactions. We were subsequently pleased to see that 66 achieved a high cell LipE
(6.4) due to improved Plasmodium potency and lower log D,
albeit with lower oral exposure and C48 h/EC50 ratio (10.9 vs
18.6) compared to 65. Further systematic exploration of SARs
at the para-position revealed that only lipophilic groups were
tolerated and identiﬁed an isopropyl group, INE963 (1),
which improved antiplasmodium activity to single digit
nanomolar (EC50 = 0.006 μM). The para-isopropyl group
increased overall compound lipophilicity, albeit without
signiﬁcantly increasing in vitro hepatic clearance. Due to
these ADME properties, INE963 (1) attained a longer T1/2
(19.2 h) with a very high C48 h/EC50 ratio (33.3) compared to
other analogs. The related 6-isopropyl-2-OEt-pyridyl analog,
67, had similar antiplasmodium potency and exposure in rats,
although with lower LipE and increased hERG inhibition (IC50
= 12 μM). Therefore, it was determined that the additional
lipophilicity of the ortho-OEt group in 67 provided minimal
advantage compared to INE963 (1). For these reasons, and
with a focus on selecting a candidate with good potential for
single dose treatment in humans, it was determined that

reduced basicity (pKa < 8), they also showed lower
Plasmodium potency (EC50’s = >0.045 μM). Transposition of
the −OH and −NH2 in 50 and 51 led to 3-hydroxy-3aminomethyl pyrrolidine analogs, 52 and 53, which increased
the antiplasmodium activity (albeit with higher pKa > 8),
however oral exposure of 52 was not comparable to the 3,4hydroxy-aminopiperidine analogs 35 and 36.
To minimize synthetic complexity and avoid the chirality of
the 3,4-hydroxy-amino piperidines and pyrrolidines, symmetrical cyclic hydroxy amines were examined. The 3hydroxy-3-aminomethyl-azetidine analog 54 had diminished
Plasmodium potency, however the 4-hydroxy-4-aminomethylpiperidine analog 55 displayed equipotency with an improved
cell LipE, as compared to 35 and 36. Transposition of the
hydroxyl and amino groups of 55 led to a lower pKa while
maintaining good potency and high cell LipE (56). Compound
55 exhibited a comparable oral PK proﬁle in rats to 35 and 36,
despite its slightly higher rat microsomal clearance, whereas 56
resulted in a 2-fold lower oral exposure in rats than 55.
Replacement of the basic amine in 55 with a second hydroxyl
group led to a signiﬁcant drop in the potency (57; EC50 = 0.49
μM), further conﬁrming the observed SAR and hypothesis that
a basic amine is required to obtain potent antiplasmodium
activity.
To probe the limits of LipE and further reduce the
lipophilicity of 55, the hydroxy group was replaced with a
carboxamide and methylsulfone to give 58 and 59, which were
signiﬁcantly less potent on Plasmodium and resulted in lower
cell LipEs. Homologation of 59 with a methylene carbon
improved the antiplasmodium activity, but 60 was still less
potent with a lower cell LipE than 55. Replacement of the
methylsulfone in 60 with a dimethylsulfonamide did not
improve the potency (61). Finally, two cyclic analogs of 55
and 56 were prepared but displayed lower Plasmodium potency
and lower cell LipE (62 and 63). Therefore, on the basis of
high cellular LipE, low inhibition of hERG, good oral exposure,
and low synthetic complexity (lack of the chirality), the 4(aminomethyl)piperidin-4-ol group (55) was prioritized as an
optimal amino-alkyl side chain for the ITD core.
Optimization of LipE and PK/PD Properties: Identiﬁcation of Clinical Candidate INE963 (1). At this stage of
the optimization, our attention turned back to the 5-aryl group,
with the aim of further increasing the antiplasmodium potency
as well oral exposure, both of which are viewed as critical
properties to improve the potential for a single dose treatment.
It was hypothesized that increasing lipophilicity would lead to
3804
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Table 5. SAR of the 5-Aryl Group in Combination with the 4-Hydroxy-4-aminomethyl-piperidine Side Chain

a
Hep CLint: In vitro hepatocyte clearance. PPB: Plasma protein binding. Cmax, AUC, T1/2: from mean blood concentration time proﬁle of oral
administration in rats at 10 mg/kg.

target in parasites has not been identiﬁed to date, but
investigations are ongoing. The mechanism of action (MoA)
appears to be novel due to the activity against multidrugresistant Pf parasite lines in addition to showing a high barrier
to resistance. To date, we have been unable to generate any
drug-resistant mutants in selection studies using multiple
protocols conducted with various Pf blood stage cultures in
vitro. The in vitro selectivity of INE963 (1) for Plasmodium vs
human cells was exempliﬁed by approximately 1000+ fold
shifts against multiple human kinase biochemical assays as well
as respectable margins in multiple cell lines used for
cytotoxicity assays (Table 6).
The fast-killing potential of INE963 (1) has been
demonstrated in a Pf viability assay (GSK, Tres Cantos)
using a limiting dilution technique to quantify the number of
Pf 3D7 parasites that remain viable after drug treatment.21,22
The results show no viable parasites after 24 h (5 log
reduction) which is comparable to or faster than artemisinin.
The in vitro log parasite reduction ratio for INE963 (1) is >8.0
at 10 × Pf 3D7 EC50 without a lag phase and a parasite
clearance time (PCT99.9) of <24 h (Table 7, Figure 5).
To assess the human kinase selectivity of INE963 (1), the
binding aﬃnities to 468 human kinases were measured at high
concentration (10 μM) and directly compared with 3, the ITD
lead compound. INE963 (1) is signiﬁcantly more selective
(only 10 out of 468 kinase were inhibited at <10% of control)

INE963 (1) had the best overall proﬁle and was progressed to
further biological characterization.
In Vitro Eﬃcacy and Selectivity. INE963 (1) was
proﬁled in numerous in vitro Plasmodium blood-stage growth
inhibition assays and shows excellent potency (Table 6). The
EC50 values of INE963 (1) are single digit nanomolar against
Pf 3D7 blood stages: EC50 = 3.0−6.0 nM. INE963 (1) is also
potent against P. falciparum and P. vivax clinical isolates from
Brazil and Uganda with EC50’s ranging from 0.01 to 7.0
nM.19,20 Additionally, INE963 (1) is active against >15 drugresistant Pf cell lines with EC50’s = 0.5−15 nM. The biological
Table 6. In Vitro Eﬃcacy and Selectivity of INE963 (1)
assays
Pf 3D7 EC50 (SYBR green)
Pf 3D7 EC50 (3H-hypoxanthine)
Brazilian isolates19 EC50 (Pf; SMA)
Brazilian isolates19 EC50 (P. vivax;
SMA)
Uganda isolates20 EC50 (Pf; SYBR
green)
human kinase IC50 (Haspin, FLT3,
PIK3CA, PIM1)
cytotoxicity CC50 (HepG2, K562,
MT4)

INE963 (1) data (μM)
0.006
0.003
0.003 (0.002−0.005) median IC50
(range)
0.002 (0.0005−0.007) median IC50
(range)
0.0004 (0.00001−0.0046) Median
IC50 (range)
5.5, 3.6, >50, >50
6.7, 6.0, 4.9
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Table 7. In Vitro P. falciparum Kill Curve Parameters of
INE963 (1)
cpd

dose

lag phase (h)

log PRRa

PCT 99.9% (h)

INE963 (1)
artemisinin

10 × EC50
10 × EC50

0
0

>8.0
>8.0

<24
<24

Drug Annotation

Table 8. In Vivo Eﬃcacy of ITD Lead Compounds in Pf 3D7
Humanized SCID Mouse Malaria Modela

Estimation based on the ﬁrst 24 h of treatment.

a

Figure 5. In vitro P. falciparum kill kinetics of INE963 (1) (PRR
assay).

with a S(10) selectivity score of 0.025. This demonstrates an
improved human kinase selectivity compared to 3 (which
inhibited 53 out of 468 human kinases at <10% of control)
with a S(10) selectivity score of 0.132 (Figure 6).23

a

Data from multiple experiments; n = 1 for four dose groups; n = 2
for compound 3; n = 1 for 3, 10, 30, and 100 mg/kg of INE963 (1); n
= 3 for 15 and 20 mg/kg of INE963 (1). Average values are showed
wherever there is more than one animal. bDose in mg/kg. cActivity =
Parasitemia reduction compared to untreated controls, in %. dDoR =
Day of recrudescence, in day. eCmax = Maximum concentration, in
μg/mL. fAUC0-23 h = Area under the curve from time 0−23 h
postdose, in μg*h/mL. gAUC0-47 h = Area under the curve from time
0−47 h postdose, in μg*h/mL.

Following four oral doses at 30 mg/kg, the frontrunner
compounds tested showed signiﬁcant parasitemia reduction
(>99.9%) at day 5 compared to untreated control mice. In
addition, the animals did not show any signs of recrudescence
of parasite at day 60 post-treatment, indicating complete cure
at these doses. Following on these promising results, INE963
(1) was further evaluated in single oral doses. In mice treated
with a single oral dose of 15 mg/kg and above, INE963 (1)
showed >99.9% parasitemia reduction at day 5 postdosing
compared to untreated control mice. The eﬀect of a single oral
dose was rapidly cidal and reached maximum killing at 15 mg/
kg. The eﬀective dose to reduce 90% parasitemia (ED90) was
determined to be 11.7 mg/kg. However, with a single dose of 3
mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg p.o., mice showed
recrudescence of parasites on day 0, day 5, day 14, and day 17,
respectively, whereas with a single dose of 30 and 100 mg/kg
p.o., mice did not show any signs of recrudescence of parasites
at day 60 post-treatment, indicating a complete cure at these
doses (Table 8, Figure 7A). Furthermore, dose-related
increases in Cmax and AUC were also observed. The threshold
exposure (AUC0−47 h) in this preclinical Pf SCID mouse model
required for 99.9% parasitemia reduction was 2.1 μg·h/mL
(Figure 7B) and for complete cure (>60 days) was 8.2 μg·h/
mL (Figure 7C). The results from this study, in conjunction
with the predictions of human PK, demonstrate INE963 (1)
has the potential for single-dose cures of uncomplicated
malaria.

Figure 6. High-concentration (10 μM) human kinase screen of 3
(left) and INE963 (1) (right).

Additionally, the IC50’s of INE963 (1) on Haspin, FLT3,
PIK3CA, and PIM1 were measured in a dose response to be
5.51, 3.60, >50.0, and >50.0 μM, respectively, which illustrates
a 600−8333-fold selectivity for Plasmodium in cell culture.
Compared to compound 3 and earlier imidazothiadiazoles
from the patent literatures,17,18 these data suggest INE963 (1)
has been substantially optimized for potency on Plasmodium
while expressly mitigating binding to human kinases.
In Vivo Eﬃcacy of INE963 (1). Based on the potent in
vitro activity, promising physicochemical properties, and in vivo
pharmacokinetics, the frontrunner compounds were proﬁled in
vivo (Table 8). Oral therapeutic eﬃcacy was evaluated against
erythrocytic asexual stages of Pf 3D7 in vivo in a humanized
severe combined immunodeﬁcient (SCID) mouse model
measuring the eﬀect on blood parasitemia by ﬂow cytometry
and microscopic analysis.24 Eﬃcacy was assessed following oral
administration of the compounds either as four doses or as one
single oral dose, and the eﬀect on blood parasitemia was
measured up to 60 days post-treatment.
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Figure 7. Parasitemia dose−response relationship of INE963 (1) in Pf 3D7 humanized SCID mouse model following one single oral dose (A) and
the exposure (AUC0−47 h) response relationship with respect to parasitemia reduction (B) and day of recrudescence (C). Data are from multiple
experiments with n = 2 for vehicle treatment in each experiment, n = 1 for 3, 10, 30, and 100 mg/kg; n = 3 for 15 and 20 mg/kg dose groups.

Pharmacokinetic Properties of INE963 (1). INE963 (1)
has high in vitro permeability of 9.9 × 10−6 cm/s based on the
low eﬄux Madin Darby canine kidney cell line (MDCK-LE)
assay. INE963 (1) is expected to be a P-gp or multidrug
resistance 1 (MDR1) protein substrate based on an eﬄux ratio
of 11.8 using transfected MDR1-MDCK cells. However, due to
high permeability, this did not signiﬁcantly impact oral
bioavailability. The free-base INE963 (1) is highly crystalline
as observed by X-ray powder diﬀraction (XRPD), and while
this form has very low solubility in water (0.0002 mg/mL),
there is a dramatic increase of the solubility in SGF and FaSSIF
(>2.0 and 1.3 mg/mL) which likely has a positive impact on
oral absorption. Overall, INE963 (1) is a lipophilic base,
log DpH7.4 = 3.1 and pKa = 8.7, with high solubility and is
classiﬁed as a BCS class III drug. INE963 (1) displays minimal
inhibition of CYP450s, with measured IC50’s ranging from 4.5
to 8.5 μM for 2C9, 2C19, 2B6, and 2C8; with all others >20
μM. Across the species tested, plasma protein binding is >99%
with low in vitro microsomal and hepatocyte clearance (CLint).
In addition, INE963 (1) exhibits high membrane and tissue
binding in vivo (i.e., high volume) which minimizes the amount
of free drug exposed to hepatic clearance and thus increases
the apparent in vivo T1/2 (Table 9).
In vivo pharmacokinetics of INE963 (1) have been studied
in mice, rats, and dogs where the absorption was moderate to
slow (Tmax 4−24 h) with good bioavailability (%F) of 39−74%
across the species. INE963 (1) has a low blood clearance
(<10% of hepatic blood ﬂow in rat and mouse and <20% of
hepatic blood ﬂow in dog) and a high volume of distribution,
resulting in long half-lives (15−24 h) across the species (Table
9).
In Vitro Metabolism of INE963 (1). The in vitro
metabolism of INE963 (1) was ﬁrst investigated following
incubation in rat, dog, and human cryopreserved hepatocytes
at 10 μM for up to 4 h, resulting in two metabolites:
hydroxylation on the isopropyl moiety (<2.5%) with
subsequent dehydration (<1.5%). Neither uptake issues
(MDCK-LE permeability = 9.9 × 10−6 cm/s) nor saturation
of metabolic enzymes were responsible for the low metabolic
turnover of INE963 (1), as high metabolic stability was also
observed in human liver microsomes at 0.5 and 6 μM. Longterm in vitro incubations may increase metabolite formation for
low turnover compounds.25,26 Subsequently, INE963 (1) was
incubated for up to 168 h in rat, dog, and human primary
hepatocyte/nonparenchymal stromal cell cocultures (at 10
μM). A summary of the in vitro metabolites obtained from this
study is provided in Figure 8. Hydroxylation and demethyla-

Table 9. Summary of Physiochemical and Pharmacokinetic
Properties of INE963 (1)
assay

INE963 (1) data

physical form by XRPD
pKa
log D7.4
solubility in water (mg/mL)
solubility in FaSSIF pH 6.5 (mg/mL)
solubility SGF pH 2.0 (mg/mL)
permeability (MDCK-LE; Papp AB × 106 cm/s)
CYP inhibition (2C9, 2C19, 2B6, 2C8, all others
>20 μM)
eﬄux ratio (MDR1-MDCK; BA/AB)
biopharmaceutical class (BCS class)
mouse, rat, dog, human PPB (% bound)
mouse, rat, dog, human microsome CLint (μL/
min/mg)
rat, dog, human hepatocyte CLint (μL/min/106
cells)
mouse, rat, dog in vivo CL (mL/min/kg)a
mouse, rat, dog in vivo Vss (L/kg)a
mouse, rat, dog in vivo half-life T1/2 (h)a
mouse, rat, dog in vivo oral bioavailability (%F)a

free base; highly
crystalline
4.0, 8.7
3.1
0.0002
1.3
>2
9.9
4.5, 5.4, 6.0, 8.5
11.8
III (up to 1000 mg
dose)
>99, >99, >99, >99
<25, 29, <25, 25.4
7.1, <4, <4
4.0, 5.9, 5.4
7.0, 8.3, 6.3
22.5, 20.4, 15.1
47, 39, 74

a

In vivo PK data from a crystalline formate-salt batch of INE963 (1),
using blood concentration.

Figure 8. In vitro metabolism of INE963 (1) following incubation in
rat, dog, and human primary hepatocyte/nonparenchymal stromal cell
cocultures at 10 μM for up to 168 h.

tion represented the main phase I metabolic pathways, whereas
acetylation (rat and human) and formylation (mainly in dog)
seemed to be the main phase II metabolic pathways in vitro.
Regardless of the species, hydroxylated INE963 (M13) was
the most intense in vitro metabolite based on mass
spectrometric responses. Moreover, all in vitro metabolites
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Table 10. Summary of Predicted Human Pharmacokinetic Parameters for INE963 (1)
PK parameter
clearance (CL)
volume steady state
(Vss)
apparent T1/2
bioavailability (F)

predicted human
value
1.6
7.2
∼60
∼70

units

notes

mL/min/kg
L/kg

based on allometric scaling method with brain weight correction
mean values from allometric scaling using single species (mouse, rat, dog)

hours
%

ﬁt to 3-compartmental model with linear elimination after IV dose (GastroPlus)
a gut PBPK model with an ACAT model after an oral dose at 1 mg/kg in IR tablet (Fed)
(GastroPlus)

of these properties position INE963 (1) as a unique
antimalarial clinical candidate with a high barrier to resistance
and the potential for single-dose cures. Ph1 clinical studies are
currently underway in healthy volunteers.

formed in human hepatocytes were also obtained following
incubation in rat or dog hepatocytes. Current investigations are
ongoing to further assess the metabolism of INE963 (1) in
vivo, which will be published at later stage.
Human Pharmacokinetic Prediction of INE963 (1).
Due to the low or no hepatic turnover in vitro, either liver
microsomal or hepatocyte assays under-predicted the in vivo
clearance observed in preclinical species. For this reason, a
direct in vitro in vivo extrapolation could not be established.
Allometry-based approaches using in vivo PK data from mice,
rats, and dogs were utilized to predict human clearance (CL)
and steady-state volume (Vss). Since no human-speciﬁc
metabolites have been observed from in vitro studies and
INE963 (1) has low CL and high Vss across all species in vivo,
the overall conﬁdence in using allometry methods is good.
Using all three species data, clearance and steady-state volume
of distribution in humans were estimated as 1.6 mL/min/kg,
and 7.2 L/kg, respectively. From these parameters, the Wajima
method was used to generate a predicted human IV time−
concentration plot, and further a gut ACAT model was used
for the prediction of a human oral PK proﬁle. The predicted
human PK parameters are summarized in Table 10. The
bioavailability is estimated to be ∼70% after a single oral dose
as an immediate release (IR) tablet under fed conditions, and
the apparent T1/2 is predicted to be long (∼60 h). Overall, the
forecasted PK proﬁle is supportive of an oral single-dose
curative therapy in patients. Based on emerging PK data from
the ﬁrst-in-human study, modeling is in progress to identify
single doses suﬃcient to maintain eﬃcacious concentrations
(estimated to be from 35 to 150 nM based on the SCID mouse
model) for multiple Plasmodium blood-stage life cycles (4−6
days).

■

SYNTHESIS

The gram-scale synthesis of INE963 (1) outlined in Scheme 1
commenced with bromination of 1,3,4-thiadiazol-2-amine (68), which

Scheme 1. Synthesis of INE963 (1)a

Reagents and conditions: (i) Br2, NaHCO3, MeOH, 0 °C, 64%; (ii)
2-chloroacetaldehyde, H2O, EtOH, reﬂux, 48 h, 20%; (iii) NIS, DMF,
RT, 37%; (iv) tBuOK, DMSO, trimethylsulfoxonium iodide, RT, then
benzylpiperidin-4-one, 94%; (v) aq. NH3, 5 °C then RT, 83%; (vi)
Boc2O, Et3N, 2-Me THF, 0 °C to RT, 62%; (vii) H2, Pd/C, MeOH,
60 °C, 70%; (viii) 76, 71, DIPEA, 2-MeTHF, 85 °C, 52%; (ix)
Fe(acac)3, NMP, THF, −50 °C, isopropyl magnesium chloride, 90%;
(x) n-BuLi, TMEDA, tri-isopropyl borate, −78 °C to RT, 87%; (xi)
77, 80, PdCl2(dppf)-DCM, aq. K3PO4, 1,4-dioxane, 90 °C, 70%; (xii)
formic acid, 0 °C to rt then NaOH, RT, 72%.
a

■

CONCLUSION
In summary, INE963 (1) oﬀers several advantageous properties as an antimalarial candidate for single-dose cure therapy of
uncomplicated malaria, including moderate-to-high bioavailability with a projected human half-life of ∼60 h. In the
humanized SCID mouse Pf malaria model, INE963 (1)
achieved 99.9% parasite reduction in blood with a single oral
dose of 15 mg/kg and a >60 days full cure with a single oral
dose of 30 mg/kg. Furthermore, INE963 (1) shows high
potency on resistant strains and ﬁeld isolates, a high barrier to
resistance in vitro, a fast-acting phenotype in Plasmodium
assays, and a MoA that is unknown but likely to be novel.
INE963 (1) also has a high degree of selectivity (>1000-fold)
against comprehensive in vitro safety panels, including human
kinases that have previously been reported as sensitive to 5aryl-2-amino-ITDs. Additionally, INE963 (1) was evaluated in
oﬀ-target safety panels, GLP safety pharmacology, genetic
toxicity, and 2-week GLP toxicity studies in rats and dogs and
was determined to have an adequate safety proﬁle for
advancement into clinical studies. Taken together, the balance

then underwent cyclization with 2-chloroacetaldehyde, followed by
iodination to furnish key intermediate 2-bromo-5-iodo-imidazothiadiazole (71). The Corey−Chaykovsky reaction of 1-benzylpiperidin4-one (72) provided the epoxide 73 in high yield, which was
subsequently opened up with ammonia before Boc-protection to yield
75. Removal of the benzyl group furnished intermediate 76 which
underwent an SnAr reaction with the bromide of key intermediate 71
to yield 77. The boronic ester 80 was prepared in two high yielding
steps starting with an iron-catalyzed addition of isopropyl Grignard
reagent to 2-chloro-6-methoxypyridine (78), followed by treatment
with n-butyllithium and subsequent reaction with tri-isopropyl borate
to yield 80. Suzuki coupling of 80 with 77, followed by Boc group
removal with formic acid, then provided INE963 (1).
Since the route described in Scheme 1 oﬀered substantial ﬂexibility
and was amenable to gram-scale synthesis of INE963 (1), we
implemented a general synthetic approach shown in Scheme 2
3808
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organic layer was concentrated and puriﬁed on silica gel (100−200
mesh, EtOAc in heptane from 16.7% to 25%) to give the title
compound (88.5 g, 20%) as yellowish solid. 1H NMR (300 MHz,
DMSO-d6): δ ppm 8.22 (d, J = 1.2 Hz, 1H), 7.39 (d, J = 0.8 Hz, 1H).
ESI MS (m/z): [M + H]+ calcd for C4H3BrN3S 203.9, found 203.9.
2-Bromo-5-iodoimidazo[2,1-b][1,3,4]thiadiazole (71). To 2bromoimidazo[2,1-b][1,3,4]thiadiazole (70) (50.0 g, 245 mmol) in
DMF (500 mL), NIS (66.1 g, 294 mmol) was added at RT on
portion, and the resulting mixture was stirred for 2.5 h. Another NIS
(11.0 g, 49 mmol) was added and stirred for another 1.5 h. The
reaction mixture was diluted with EtOAc (2.0 L), and then the
reaction mixture was washed with aqueous Na2S2O3 solution (500
mL). The organic layer was washed with ice cooled water (3 × 250
mL) and further washed with brine (250 mL), dried over anhydrous
Na2SO4, ﬁltered, and concentrated. The residue was slurried in
MeCN (100 mL) for 30 min, and the solid was ﬁltered and washed
with MeCN (50 mL) to give the title compound (40.4 g, 37%) as
white solid. 1H NMR (400 MHz, DMSO-d6): δ ppm 7.43 (s, 1H).
ESI MS (m/z): [M + H]+ calcd for C4H2BrIN3S 329.8, found 329.7.
6-Benzyl-1-oxa-6-azaspiro[2.5]octane (73). tBuOK (177.9 g, 1.59
mol) was added in portions to DMSO (2.0 L) at RT under N2, then
trimethylsulfoxonium iodide (319.8 g, 1.45 mol) was added in portion
slowly over 15 min at RT. The resulting solution was stirred at RT for
1 h. A solution of 1-benzylpiperidin-4-one (72) (250 g, 1.32 mol) in
DMSO (0.5 L) was added at RT over 30−40 min. The reaction was
stirred at RT for 1 h, then the solution was quenched with water (2.5
L) and extracted with MTBE (2.5 L × 2). The combined organic
layers were washed with brine (2.5 L), dried over Na2SO4, ﬁltered,
and concentrated to give the title compound (253 g, 94%) as
yellowish liquid. 1H NMR (400 MHz, DMSO-d6): δ ppm 7.26−7.38
(m, 5H), 3.59 (s, 2H), 2.55−2.67 (m, 5H), 1.82−1.89 (m, 2H),
1.57−1.60 (m, 2H). ESI MS (m/z): [M + H]+ calcd for C13H18N
204.1, found 204.1.
4-(Aminomethyl)-1-benzylpiperidin-4-ol (74). To 6-benzyl-1-oxa6-azaspiro[2.5]octane (73) (250 g, 1.23 mol) in MeOH (1.5 L),
aqueous ammonia (3 L, 4.15 mol) was added dropwise at 5−10 °C
over 15 min. The resulting mixture was stirred at RT for 16 h and
diluted in DCM (3.5 L). The aqueous layer was separated and
extracted with DCM (3 L × 3). The combined organic layers were
washed with NaOH (1 N, 3 L) and brine (3 L), dried on Na2SO4, and
concentrated to give the title compound (225 g, 83%) as oﬀ-white
solid, which was used for next step without further puriﬁcation.
tert-Butyl ((1-Benzyl-4-hydroxypiperidin-4-yl)methyl)carbamate
(75). 4-(Aminomethyl)-1-benzylpiperidin-4-ol (74) (430 g, 1.95 mol)
was suspended in 2-Me THF (8.6 L), and Et3N (197.5 g, 1.95 mol)
was added before the reaction was cooled to 0 °C. Then a solution of
Boc2O (511.5 g, 2.34 mol) in 2-Me THF (400 mL) was added
dropwise at 0 °C over 20 min. The resulting solution was stirred for
16 h, and the mixture was quenched with water (2 L) and brine (2 L).
The organic layer was washed with brine (2 × 2 L), dried over
Na2SO4, ﬁltered, concentrated, and puriﬁed by silica gel (60−120
mesh) using an initial elution with 50−80% EtOAc in hexanes then
5−20% MeOH in DCM to give the title compound (396 g, 62%) as
oﬀ-white solid. 1H NMR (400 MHz, CDCl3): δ ppm 7.24−7.32 (brs,
5H), 4.90 (s, 1H), 3.53 (s, 2H), 3.15 (d, J = 6.0 Hz, 2H), 2.59−2.62
(m, 2H), 2.30−2.40 (m, 3H), 1.56−1.67 (m, 4H), 1.44 (s, 9H). ESI
MS (m/z): [M + H]+ calcd for C18H29N2O3 321.2, found 321.2.
tert-Butyl ((4-Hydroxypiperidin-4-yl)methyl)carbamate (76). tertButyl ((1-benzyl-4-hydroxypiperidin-4-yl)methyl)carbamate (75)
(363.0 g, 1.13 mol) was dissolved in MeOH (2.5 mL) before Pd/C
(90.75 g, 20%) was added under N2. The resulting mixture was
evacuated with hydrogen gas and given 15 kg/cm2 of pressure. The
mixture was stirred for 16 h at 60 °C, then was ﬁltered through a
Celite bed, washed with MeOH (2 L), and concentrated. The crude
product was slurried in IPA (700 mL), ﬁltered, and washed with IPA
(200 mL) to give the title compound (180 g, 70%) as white solid. 1H
NMR (400 MHz, CDCl3): δ ppm 4.95 (brs, 1H), 3.13−3.21 (d, J =
6.0 Hz, 2H), 2.91−2.97 (m, 2H), 2.82−2.87 (m, 2H), 2.08 (brs, 2H),
1.47−1.54 (m, 4H), 1.43 (s, 9H). ESI MS (m/z): [M + H]+ calcd for
C11H23N2O3 231.2, found 231.1.

Scheme 2. General Pathway to Synthesize
Imidazothiadiazole Analogsa

a

Reagents and conditions: (i) RR′NH, DIPEA, CH3CN or NMP or
DMSO, 90−110 °C; (ii) R″-boronic acid/ester, PdCl2(dppf)-DCM
(5 mol %), aq. K3PO4, 1,4-dioxane, 80−90 °C; (iii) HCl or HCOOH
or TFA, 0 °C to RT.
starting with the key intermediate ITD 71. A facile SnAr reaction with
a variety of primary and secondary amines furnished the 2-aminosubstituted imidazothiadiazole 82 in a moderate to high yield.
Subsequently, cross-coupling with a range of diﬀerent boronic acids/
esters using palladium catalysis followed by Boc deprotection gave the
target compounds 83.
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EXPERIMENTAL SECTION

General Procedures. All materials and reagents used were of the
best commercially available grade and used without further
puriﬁcation. Normal-phase column chromatography was carried out
using prepacked silica gel cartridges on a Combiﬂash Rf separation
system by Teledyne ISCO. 1H NMR spectra were determined on a
Varian 400 or Bruker 300 or 400 and 500 MHz NMR spectrometers.
The following abbreviations are used: s = singlet, d = doublet, dd =
doublet of doublets, t = triplet, q = quartet, m = multiplet, bs = broad
singlet. Preparative HPLC was performed on a Waters Prep HPLC
system using a C18 reversed-phase column eluting with gradient
mixtures of water/acetonitrile containing a modiﬁer 0.05% triﬂuoroacetic acid. All compounds >95% purity by HPLC analysis. The purity
of the ﬁnal compounds was conﬁrmed by UPLC-MS and UPLC.
Additionally, all ﬁnal compounds presented with in vivo data have
been conﬁrmed by 1H NMR, LCMS, and HRMS in the Supporting
Information. The human biological samples were sourced ethically,
and their research use was in accord with the terms of the informed
consents under an IRB/EC approved protocol. All animal studies
were ethically reviewed and carried out in accordance with European
Directive 2010/63/EEC and the GSK Policy on the Care, Welfare,
and Treatment of Animals. Human erythrocytes for in vivo studies
were obtained from the Basque Center of Transfusion and Human
Tissues, Galdakao, Spain; the Centro de Transfusiones de la
Comunidad de Castilla y León, Valladolid, Spain; and the Bank of
Blood and Tissues, Barcelona, Spain. Clinical isolate assays in Brazil
and Uganda were performed as previously described.19,20
5-Bromo-1,3,4-thiadiazol-2-amine (69). To 1,3,4-thiadiazol-2amine (68) (500 g, 4.95 mol) in MeOH (5 L), NaHCO3 (830.9 g,
9.89 mol) was added at room temperature (RT). The mixture was
cooled to 0−5 °C, and bromine (792.0 g, 4.95 mol) was added
dropwise over a period of 1 h. The mixture was warmed to RT and
stirred for 3 h, and the solid was ﬁltered and washed with MeOH
(500 mL). The solid was slurried in water (10 L) for 1 h and collected
and washed with water (1 L). The solid was slurried in MeOH (1.5
L), ﬁltered, and washed with MTBE (1 L) to give the title compound
(554.0 g, 64%) as yellowish solid. 1H NMR (400 MHz, DMSO-d6): δ
ppm 7.51 (brs, 2H). ESI MS (m/z): [M + H]+ calcd for C2H3BrN3S
179.9, found 179.9.
2-Bromoimidazo[2,1-b][1,3,4]thiadiazole (70). To a mixture of 5bromo-1,3,4-thiadiazol-2-amine (69) (500.0 g, 2.78 mol) in water and
EtOH (1:1; 5 L) was added a 44% aqueous solution of 2chloroacetaldehyde (1425.9 g, 7.78 mol) over a period of 15 min at
RT. The reaction mixture was heated at reﬂux over a period of 1 h and
stirred for 48 h. After completion of the reaction, the reaction mixture
was quenched with 8% aqueous solution of sodium bicarbonate (5 L),
and EtOAc (10 L) was added to it. The mixture was stirred for 10 min
at RT. The reaction mixture was ﬁltered through Celite bed, and bed
was washed with EtOAc (1.0 L). The organic layer was separated, and
an aq. layer was extracted with EtOAc (1.0 L × 2). The combined
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Celite at 30 °C, and washed with DCM (340 mL). The ﬁltrate was
evaporated under reduced pressure followed by codistillation with
MTBE (2 × 850 mL) and slurried in MTBE (850 mL) for 1 h at 30
°C. The solids were ﬁltered, washed, and dried further to give the title
compound (123 g, 70%) as a white solid. 1H NMR (400 MHz,
CDCl3): δ ppm 8.50 (d, J = 7.6 Hz, 1 H), 7.68 (s, 1 H), 6.83 (d, J =
7.6 Hz, 1 H), 5.02 (bs, 1 H), 4.06 (s, 3 H), 3.71−3.69 (m, 2H), 3.56−
3.49 (m, 2H), 3.18 (d, J = 6.4 Hz, 2 H), 2.96 (quintet, J = 6.8 Hz, 1
H), 1.78−1.61 (m, 6H), 1.45 (s, 9H), 1.25 (m, 6H). ESI MS (m/z):
[M + H]+ calcd for C24H35N6O4S 503.2, found 503.3.
4-(Aminomethyl)-1-(5-(6-isopropyl-2-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-ol (INE963; 1). tertButyl ((4-hydroxy-1-(5-(6-isopropyl-2-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-yl)methyl)carbamate (81)
(50 g, 0.099 mol) was collected to 0 °C before formic acid (80
mL, 9.95 mol) was slowly added under N2 atmosphere. The reaction
mixture was allowed to warm to RT and continue to stir for 7 h at RT.
The excess of formic acid was evaporated under reduced pressure at
30 °C and then codistilled with MeCN (5 × 360 mL). The resulting
solids were slurried in MeCN (3.6 L) and stirred for 1 h at RT and
then at 10 °C for 1 h. The solids were washed with MeCN (150 mL)
and then dried to obtain 37 g of formate salt. Combined with another
similar batch size, the formate salt (72 g) was dissolved in water (580
mL), and a solution of NaOH (20% in Water, 72 mL) was added to
adjust the pH to 13. The mixture was stirred for 1 h at RT. The solids
were ﬁltered and washed with water (360 mL), then washed with
MTBE (360 mL), and ﬁnally dried under vacuum for 16 h. The solids
were taken again in water (720 mL) and stirred for 2 h at RT. The
solids were ﬁltered, washed with water (360 mL), washed with MTBE
(360 mL), and then dried under vacuum at 45 °C for 48 h to give the
title compound (62 g, 72%). 1H NMR (300 MHz, DMSO-d6) δ 8.55
(d, J = 7.7 Hz, 1H), 7.56 (s, 1H), 7.00 (d, J = 7.8 Hz, 1H), 4.42 (s,
1H), 4.00 (s, 3H), 3.65 (dd, J = 10.4, 6.5 Hz, 2H), 3.8−3.41 (m, 2H),
3.33 (s, 2H), 2.97 (h, J = 6.8 Hz, 1H), 1.63−1.56 (m, 4H), 1.26 (d, J
= 6.9 Hz, 6H). ESI HRMS [M + H]+ for C19H27N6O2S calcd
403.1911, found 403.1907. LCMS Rt: 2.65 min; purity: >99%.
Pf 3D7 Phenotypic Assay. Following an established Pf
protocol,27 parasite cultures were grown in media (RPMI 1640
medium (10.4 g/L) with 0.5% Albumax II, 200 μM hypoxanthine, 50
mg/L gentamicin sulfate, 35 mM Hepes, 2.0 g/L sodium bicarbonate,
and 11 mM glucose) and human erythrocytes. Cultures were
maintained at 37 °C in an incubator with 5% CO2. In vitro
antiplasmodium activity was measured according to a modiﬁed SYBR
Green cell proliferation assay.28 Dose−response curve data were
normalized based on ﬂuorescence signal values from DMSO treated
wells (0% inhibition) and meﬂoquine treated wells (100% inhibition)
at a ﬁnal concentration of 10 μM. The standard logistic regression
model was applied for curve ﬁtting in order to determine the EC50.29
HepG2 Cytotox Assay. HepG2 are adherent cells that were
maintained in Dulbecco’s modiﬁed Eagle’s medium-F12 supplemented with 1% penicillin/streptomycin and 10% heat-inactivated
FBS. Fifty μL of a 5 × 104 cells/mL suspension were dispensed in
white, solid 384-well plates (Greiner). Cells were exposed to
compounds for 72 h, after which cell viability was quantiﬁed by
using CellTiter-Glo. This reagent measures ATP release based on the
mono-oxygenation of luciferin catalyzed by Mg2+, ATP, and molecular
oxygen. EC50 values were calculated from two independent experiments performed in triplicate using the Graphpad Prism software. The
standard logistic regression model was applied for curve ﬁtting in
order to determine the EC50.29
Haspin Kinase assay. The assay was done in assay buﬀer
consisting of 50 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic
acid or HEPES at pH 7.5, 5 mM MgCl2, 0.01% Tween-20, 0.1%
glycerol, 0.5 mM (tris(2-carboxyethyl)phosphine) or TCEP, and
0.01% bovine serum albumin. All reaction was performed at RT.
Compounds were prespotted and incubated with 10 mL of assay
buﬀer containing 0.05 pM of human Haspin kinase domain for 30
min. The reaction was initiated by adding 10 mL of assay buﬀer
containing 0.3 nM H3 biotin peptide and 30 mM of ATP for 90 min.
The assay was stopped with 100 mM EDTA. The luminescence signal

tert-Butyl ((4-Hydroxy-1-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol2-yl)piperidin-4-yl)methyl)carbamate (77). A mixture of tert-butyl
((4-hydroxypiperidin-4-yl)methyl)carbamate (76) (155 g, 076 mol),
2-bromo-5-iodoimidazo[2,1-b][1,3,4]thiadiazole (233.2 g, 0.71 mol),
and DIPEA (174.0 g, 1.35 mol) in 2-MeTHF 1.55 L, 10 V) was
heated to 85 °C for 9 h. The reaction was stirred in water (10 V) at
RT for 15 min before the layers were separated. The aqueous layer
was extracted twice with EtOAc (2 × 10 V). The combined organic
layers were washed with brine, dried over Na2SO4, ﬁltered,
concentrated, and triturated in DCM (5 V) for 1 h at RT. The
suspension was ﬁltered, washed with DCM (1 V), and dried under
vacuum to give the title compound (168 g, 52%) as light brown solid.
1
H NMR (400 MHz, MeOD-d4): δ ppm 7.06 (s, 1H), 2.69−3.72 (m,
2H), 3.45−3.52 (m, 2H), 3.11 (s, 2H), 1.63−1.76 (m, 4H), 1.44 (s,
9H). ESI MS (m/z): [M + H]+ calcd for C15H22IN5O3S 480.1, found
480.0.
2-Isopropyl-6-methoxypyridine (79). To a solution of 2-chloro-6methoxypyridine (78) (90 g, 0.63 mol) in THF (810 mL) and NMP
(90 mL) was added Fe(acac)3 (2.21 g, 1 mol %) at RT. The reaction
mixture was purged with N2 for 30 min at RT and then cooled to −50
°C before slow addition of a solution of isopropyl magnesium chloride
in THF (96.71 g, 1.5 equiv) over 1.5 h. The reaction mixture was
stirred for 30 min. The reaction mixture was quenched with water (2
equiv) slowly at −40 °C, then warmed to 0 °C, followed by the
addition of 1.5 N HCl (90 mL) at 0−5 °C (highly exothermic) and
further diluted with water (800 mL). The mixture was diluted with
MTBE (900 mL). The organic layer was separated and washed with
water (5 × 900 mL), dried over Na2SO4, distilled under vacuum at 40
°C, and further dried under high vacuum for 2 h at 40 °C to give the
title compound (86 g, 90%). 1H NMR (400 MHz, CDCl3): δ ppm
7.48−7.46 (m, 1H), 6.72−6.70 (d, J = 8 Hz, 1H), 6.53−6.51 (m, 1H),
3.92 (m, 3H), 3.02−2.90 (m, 1H), 1.28−1.26 (m, 6H). ESI MS (m/
z): [M + H]+ calcd for C9H14NO 152.1, found 152.1.
(6-Isopropyl-2-methoxypyridin-3-yl)boronic Acid (80). To a
solution of 2-isopropyl-6-methoxypyridine (79) (100 g, 0.66 mol)
in THF (810 mL) was added TMEDA (80.7 g, 0.69 mol) at RT
under N2 atmosphere. The resulting mixture was cooled to −78 °C,
and slowly n-BuLi (2.5 M in hexane, 63.48 g, 0.99 mol) was added.
The reaction was allowed to reach RT and was stirred for 1 h at RT.
Further, the reaction was cooled to −78 °C, and then tri-isopropyl
borate (286.1 g, 1.52 mol) was slowly added. The reaction was
warmed to RT and was stirred for 3 h at RT. After completion, the
reaction was cooled to 0 °C, quenched with 1.5 N HCl (400 mL) at 0
°C, and further diluted with water (400 mL). The aqueous layer was
extracted with EtOAc (400 mL). The organic layer was washed twice
with brine (800 mL), dried over Na2SO4, distilled under vacuum at 30
°C, and puriﬁed on silica gel (EtOAc/Hexane) to give the title
compound (123 g, 95%). 1H NMR (400 MHz, CDCl3): δ ppm 8.05−
7.99 (m, 1H), 6.91−6.78 (m, 1H), 6.03 (s, 1H), 4.07−4.03 (m, 3H),
3.00−2.93 (m, 1H), 1.35−1.22 (m, 6H).
tert-Butyl ((4-Hydroxy-1-(5-(6-isopropyl-2- methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-yl)methyl)carbamate (81). To a solution of (6-isopropyl-2-methoxypyridin-3yl)boronic acid (80) (170 g, 0.35 mol) and tert-butyl ((4-hydroxy-1(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)piperidin-4-yl)methyl)carbamate (77) (76.08 g, 0.39 mol) in 1,4-dioxane (1.7 L) under N2
atmosphere was added a prepared solution of K3PO4 (225.85 g, 1.064
mol) in water (340 mL). The reaction mixture was purged under N2
gas for 15 min before Pd(dppf)Cl2.DCM (20.27 g, 0.025 mol) was
added. The reaction mixture was heated to 85 °C for 16 h. The
reaction was treated with water (3.4 L) for 30 min at RT and then at
10 °C for 1 h. The resulting solids were washed with water (850 mL),
dried under vacuum, and further washed with MTBE (1.5 mL). The
isolated solid was puriﬁed on silica gel (2−3% MeOH/DCM),
followed by MTBE slurry of the major fraction, resulting in an oﬀwhite solid. The product was dissolved in DCM (3.4 L) and heated to
40 °C. The resulting solution was treated with siliabond thiol (30 wt
%) at 40 °C for 6 h before it was ﬁltered through Celite bed at 30 °C
and washed with DCM (340 mL). The ﬁltrate was resubjected to
siliabond thiol (30 wt %) treatment at 40 °C for 6 h, ﬁltered through
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was detected by adding using 10 mg/mL of streptavidin donor beads
and 42 ng/mL of antiphospho-histone H3 (Thr3) antibody together
with 10 mg/mL protein A acceptor beads. The plates were brieﬂy
spun, sealed, and incubated in the dark overnight before reading them
with Envision.
Pf 3D7 Phenotypic Resistance Selection Methods. Three
diﬀerent protocols were used to raise resistance against ITD leads in
Pf blood stages. Culture conditions were as described. Asexual
parasites were exposed to a drug concentration of 3 × IC50 at a single
inoculum of 109 parasites in duplicates. The parasites cleared from the
culture within days. The cultures were maintained and monitored for
parasites growth on a routine basis. When no parasites recrudesced
within 60 days, the cultures were discarded. The experiment was
repeated in the presence of 5 μM ethylmethanesulfonate (EMS), a
mutagen that increases the chance for resistance development. 109
parasites were incubated in duplicate for 2 h with EMS prior to
applying the drug pressure to raise resistant parasites. Cultures were
again monitored for 60 days before discarding them after no
recrudescence was observed. Lastly, we exposed parasites to low
doses of drug cycling over a period of 7 months. 108 parasites were
maintained between 0.5% and 10% parasitemia and exposed to short
pulses of drug incubation (1−4 days). After each treatment, the drug
was removed, and parasites were allowed to recover. The drug
concentration was slowly raised from 0.5 × to 8 × IC50, but parasites
either failed to recover or did not show a resistant phenotype as
measured by 72 h growth inhibition assays. The experiment was run
in duplicate and four biological replicates.
In Vivo Eﬃcacy Studies using P. falciparum SCID Mouse
Model. In vivo animal experiments were performed at The Art of
Discovery SL. These studies were approved by The Art of Discovery
Institutional Animal Care and Use Committee (TAD-IACUC). The
committee is certiﬁed by the Biscay County Government (Bizkaiko
Foru Aldundia, Basque Country, Spain) to evaluate animal research
projects from Spanish institutions according to point 43.3 from Royal
Decree 53/2013, from the ﬁrst of February (BOE-A-2013-1337). All
experiments are carried out in accordance with European Directive
2010/63/EU.
The compound eﬃcacy was assessed in the murine P.falciparum
SCID model as described previously. Brieﬂy, 22−28 g female NODSCID IL- 2Rγnull mice (NSG) (Charles River, France) previously
engrafted with human erythrocytes (>40% of human erythrocytes in
peripheral blood) were intravenously infected with Pf 3D70087/N9infected erythrocytes (0.3 mL of 1.17 × 108 parasitized-erythrocytes
per mL) 72 h before drug treatment inception. At this point (day 1 of
the study), mice had 1−2% of parasitemia on average, and the mice
were randomly allocated to selected treatments. Compound was
formulated in 0.5% methylcellulose and 0.5% Tween 80 in double
distilled water administered by oral gavage at 10 mL/kg dose volume
on day 1 of the study either as four oral doses or one single oral dose.
The eﬀect of treatment on parasitemia was assessed by measuring the
percentage of infected erythrocytes in peripheral blood every 24 h
until parasitemia was below the selected limit of quantitation (usually
0.01%) by ﬂow cytometry. The parasitemia in mice was regularly
measured up to day 60 of experiment to check the presence of
circulating parasitized human erythrocytes. In addition, during the
study, samples of peripheral blood were taken between 0 and 71 h
postdose from mice to measure the concentration of drugs in blood
after oral administration. The drugs were extracted from blood
samples by protein precipitation using standard liquid−liquid
extraction. Brieﬂy, 10 μL of blood samples were mixed with 60 μL
of acetonitrile containing internal standard (100 ng/mL of trimipramine-d3 in methanol), vortexed, and centrifuged, 60 μL of
supernatant was mixed with 55 μL of water. These samples were
analyzed by LC-MS/MS for quantiﬁcation in a Waters Micromass
UPLC-TQD (Waters, Manchester, UK) under optimized conditions.
Data analysis is performed using Phoenix WinNonlin version 7.0
(Certara) to calculate PK parameters via noncompartmental analysis.
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ABBREVIATIONS USED
acac, acetylacetonate; ADME, absorption, distribution, metabolism, and excretion; AUC, area under the curve; Boc2O, ditert-butyl dicarbonate; CL, clearance; DCM, dichloromethane;
EC50, half-maximal eﬀective concentration; ED50, eﬀective dose
50; FaSSIF, fasted state simulated intestinal ﬂuid; ITD,
imidazothiadiazole; 2-MeTHF, 2-methyltetrahydrofuran;
MMV, Medicines for Malaria Venture; MTBE, methyl tertbutyl ether; NIS, N-iodosuccinimide; NMP, N-methyl-2pyrrolidone; Pd(dppf)Cl2·DCM, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane; Pf , Plasmodium falciparum; PPB,
plasma protein binding; RT, room temperature; SAR,
structure−activity relationship; SCID, severe combined
immunodeﬁciency; T1/2, half-life; TMEDA, tetramethylethylenediamine; Vss, volume steady state
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